Loading company…
Cambridge-based biotechnology company developing cancer therapies that target metabolic pathways in tumors.
Founded in Cambridge, US, Raze Therapeutics develops cancer therapies that target metabolic dependencies of tumors. It raised USD 19.80 mn in Series A funding on October 14, 2014, from investors including Atlas Venture and Novartis, establishing a company valuation of USD 29.19 mn. The company plans to use its Series A funding to accelerate research and development and support clinical trials.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in